Vericel News and Activities
Presence
Vericel develops and markets cell therapies and tissue repair products. It serves hospitals, surgeons, and patients in orthopedic, burn care, and severe wound treatment.
Vericel products and services overview:
- Cell therapies
- Cartilage repair
- Burn care
- Wound repair
Revenue: ~$238 million
Employees: 360
Headquarters: Cambridge, United States (USA)
Vericel is one of the...
Vericel is a company listed under the stock ticker VCEL (US).
Executives
View the org chart displaying its 28 main executives
Most searched biographies at Vericel
- Dominick Colangelo, Director, President and Chief Executive Officer
- Kevin McLaughlin, Director
- Lisa Wright, Director
Create your alert
to follow the executive moves at Vericel.
Biotechnology
Vericel has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
- NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (posted on June 1 2026)..
Popular contacts in Biotechnology
News
Press releases by Vericel
- Press Releases | Vericel Corporation
- Vericel Reports Second Quarter 2022 Financial Results | Vericel Corporation
- Press Releases | Vericel Corporation
- Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel | Vericel Corporation
- Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022 | Vericel Corporation
- Vericel Reports First Quarter 2022 Financial Results | Vericel Corporation
- Vericel Announces Preliminary Third Quarter 2020 Total Net Revenues of $32 Million | Vericel Corporation
- Vericel Corporation | Advanced cell therapies
- Vericel To Host Virtual Analyst and Investor Day on October 16, 2020 | Vericel Corporation
- Vericel Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns | Vericel Corporation
- View more press releases Close
Social media about Vericel
- Vericel on Wikipedia, Google News & Yahoo Finance
- Vericel on LinkedIn, X (Twitter) & YouTube
